Health Care · Pharmaceutical Preparations

AQST Aquestive Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1398733110 filings
Russell 2000

AQST at a glance

Aquestive Therapeutics, Inc. (AQST, SEC CIK 1398733) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.5 million (down 22.6% from FY2024) and a net loss of $83.8 million. Diluted EPS was -$0.78.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Aquestive Therapeutics, Inc. (AQST) shares worth $129.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Davis Matthew W. on November 12, 2026 of 7,197 shares at $3.55 per share.
  • In the last 90 days, AQST insiders reported 2 open-market purchases ($99K) and 4 open-market sales ($297K) on Form 4, a net sale of $198K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$44.5M
−22.6% vs prior year
Insiders · 90 days
2 buys · 4 sells
Net −$198K
13F holders
26 funds
$129.4M · +1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $7,557, down 41% YoY from $12,807, driven by Suboxone revenue decline of approximately $5,600
  • Manufacture and supply revenue $6,659, down 42% YoY, with Ondif revenue up approximately $1,100
  • Operating margin not disclosed; R&D expense $4,251, down 6%, and SG&A $14,169, down 7%
  • Cash $90,349 at September 30; operating cash use $31,293 versus $43,963 YoY
  • Anaphylm resubmission accepted as Class 2; FDA PDUFA goal March 16, 2027, launch readiness targeted for Q1 2027 if approved

Risk Factors

  • No material changes disclosed from the 2025 Form 10-K and subsequent 10-Q filings
  • Carried-forward business risk: adverse effects on prospects, financial condition, results, liquidity, and available capital resources
  • Risk disclosure incorporates prior filings without identifying a new trigger or updated regulatory, operational, competitive, or financial detail

AI summary of the AQST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor presentation disclosed at the Jefferies Global Healthcare Conference on November 16, 2026
  • Presentation provides management’s latest investor messaging and may influence analyst expectations

Item EX-99.1: Item EX-99.1

  • Anaphylm NDA resubmission accepted, with FDA PDUFA goal date March 16, 2027, creating a major near-term regulatory catalyst
  • Cash and equivalents $90.3 million at September 30, 2026, with potential access to $75 million RTW funding and $20 million Oaktree debt
Filed Nov 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor presentation disclosed under Regulation FD for institutional investor and analyst meetings
  • Presentation likely contains current strategic, pipeline, or financial updates, with details in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Anaphylm NDA resubmission accepted, with FDA PDUFA goal date March 16, 2027
  • Regulatory catalyst remains binary: FDA may approve, request additional information, or issue another rejection
Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced
  • Business update included alongside financial results

Item 7.01: Regulation FD Disclosure

  • Investor presentation furnished for institutional investor and analyst meetings
  • Presentation may contain updated corporate, pipeline or financial information relevant to AQST valuation

Item EX-99.1: Item EX-99.1

  • Anaphylm NDA resubmission accepted as Class 2, with FDA PDUFA goal date March 16, 2027
  • Potential first oral rescue treatment for anaphylaxis, creating meaningful commercial upside if approved

Item EX-99.2: Item EX-99.2

  • Anaphylm NDA resubmitted in Q3 2026, with FDA PDUFA goal date March 16, 2027
  • Commercial launch preparations remain on track, but revenue upside depends on FDA approval and market adoption

AI summaries of AQST 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AQST

Don't miss the next AQST filing

  • Alerts as it files. A push when AQST files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AQST, by share count.
  • Ask anything. An AI agent that reads every AQST filing and answers with sources.

AQST alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Davis Matthew W.SellNov 12, 2026$3.55
Davis Matthew W.FNov 10, 2026$3.52
Daly Richard JBuyNov 10, 2026$3.53
Daly Richard JBuyNov 10, 2026$3.54
Daly Richard JANov 6, 2026-
Cochran JohnJOct 21, 2026-
Barber DanielSellOct 15, 2026$4.22
Barber DanielSellSep 15, 2026$4.82

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$57.6M$44.5M
Operating Income--$30.8M-$71.1M
Net Income-$7.9M-$44.1M-$83.8M
Op. Margin--53.5%-159.5%
Net Margin--76.7%-188.1%
Balance Sheet
Total Assets$57.4M$101.4M$160.4M
Equity--$60.2M-$33.7M
ROE-73.4%248.9%
Per Share
EPS$-0.13$-0.51$-0.78
Cash Flow
Operating CF--$35.8M-$52.4M
CapEx$995K$159K$562K

Source: XBRL data in Aquestive Therapeutics, Inc. (AQST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AQST share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AQST shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$129.4M
Q2 202625$101.1M
Q1 202625$98.8M
Q4 202524$175.0M
Q3 202523$119.7M
Q2 202521$68.4M
Q1 202519$34.9M
Q4 202417$36.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AQST filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
4Nov 16, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 10, 2026--
8-KNov 5, 2026Analysis-
10-QNov 3, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 23, 2026--
8-KOct 19, 2026Analysis-
4Oct 16, 2026--
8-KOct 15, 2026Analysis-
8-KOct 14, 2026Analysis-
8-KSep 29, 2026Analysis-
8-KSep 25, 2026Analysis-
8-KSep 17, 2026Analysis-
4Sep 16, 2026--
4Sep 11, 2026--
4Sep 10, 2026--
4Sep 9, 2026--
4Sep 8, 2026--
4Aug 18, 2026--
4Aug 17, 2026--
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis

Related Health Care companies

All Health Care →

AQST SEC filings: frequently asked questions

Are AQST insiders buying or selling?

In the last 90 days, Aquestive Therapeutics, Inc. (AQST) officers, directors and 10% owners reported 2 open-market purchases worth $99,331 by 1 insider and 4 open-market sales worth $297,289 by 3 insiders on Form 4, a net sale of $197,958. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AQST stock?

As of September 30, 2026, the largest Aquestive Therapeutics, Inc. (AQST) holders among the 13F filers tracked by SignalX were BlackRock ($38.0 million), Vanguard Capital Management LLC ($22.2 million), State Street Corp ($16.1 million), Two Sigma Investments ($8.2 million), D.E. Shaw & Co ($5.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AQST's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.5 million (down 22.6% from FY2024) and a net loss of $83.8 million. Diluted EPS was -$0.78. The figures come from the XBRL data in the 10-K.

What did AQST report in its latest 8-K?

Aquestive Therapeutics, Inc. (AQST) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation disclosed at the Jefferies Global Healthcare Conference on November 16, 2026.

What are the latest AQST SEC filings?

Aquestive Therapeutics, Inc. (AQST) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 16, 2026.

What is AQST's SEC CIK number?

Aquestive Therapeutics, Inc. (AQST)'s SEC Central Index Key (CIK) is 1398733. EDGAR lists every AQST filing under that number.

Ask anything about AQST

The research agent reads AQST's filings, financials, insider trades and 13F holders, then answers with sources.